Applied Therapeutics Inc - Asset Resilience Ratio
Applied Therapeutics Inc (APLT) has an Asset Resilience Ratio of 0.17% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check APLT capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2023)
This chart shows how Applied Therapeutics Inc's Asset Resilience Ratio has changed over time. See Applied Therapeutics Inc balance sheet quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Applied Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Applied Therapeutics Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $253.00K | 0.17% |
| Total Liquid Assets | $253.00K | 0.17% |
Asset Resilience Insights
- Limited Liquidity: Applied Therapeutics Inc maintains only 0.17% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Applied Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Applied Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 10.93% |
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 57.90% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 0.72% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX |
Biotechnology | 87.20% |
|
Tourmaline Bio Inc.
NASDAQ:TRML |
Biotechnology | 77.17% |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230 |
Biotechnology | 16.35% |
Annual Asset Resilience Ratio for Applied Therapeutics Inc (2017–2023)
The table below shows the annual Asset Resilience Ratio data for Applied Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | $0.00 | $54.83 Million | -- |
| 2022-12-31 | 36.29% | $13.92 Million | $38.36 Million | +6.33pp |
| 2021-12-31 | 29.96% | $26.93 Million | $89.89 Million | -7.70pp |
| 2020-12-31 | 37.67% | $39.36 Million | $104.51 Million | -3.67pp |
| 2019-12-31 | 41.34% | $20.00 Million | $48.39 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $20.25 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $3.29 Million | -- |
About Applied Therapeutics Inc
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric cli… Read more